

Pharmaceutical Benefits Scheme (PBS) Listings

1 July 2026

Please find below information relating to new and amended Pharmaceutical Benefits Scheme (PBS) listings implemented on **1 July 2026**.

This information relates to the administration of these listings by Services Australia. For further information on broader PBS changes, please visit the PBS website. Relevant information and authority application forms have been updated and can be accessed through the Services Australia website.

Generalised myasthenia gravis (gMG)

Rozanolixizumab (280 mg/2 mL injection, 2 mL vial) (Rystiggo®) is now listed on the PBS for the treatment of gMG. Authority applications for the treatment of acute severe gMG, bridging therapy, and for initial, continuing and grandfather treatments of treatment refractory gMG can be made using the Online PBS Authorities system or in writing.

Uncontrolled severe asthma

Tezepelumab (210 mg/1.91 mL injection, 1.91 mL pen device) (Tezspire®) is now listed on the PBS for the treatment of uncontrolled severe asthma in patients 12 years or older. Authority applications for initial, continuing and grandfather treatments can be made using the Online PBS Authorities system or in writing.

Short stature associated with biochemical growth hormone deficiency; Short stature and slow growth

Somapacitan (10 mg/1.5 mL injection, 1.5 mL pen device; 15 mg/1.5 mL injection, 1.5 mL pen device) (Sogroya®) is now listed on the PBS for the treatment of short stature associated with biochemical growth hormone deficiency and short stature and slow growth. Authority applications for initial, continuing, change, recommencement and grandfather treatments can be made using the Online PBS Authorities system or in writing.

Severe Crohn disease; moderate to severe ulcerative colitis; complex refractory Fistulising Crohn disease; severe psoriatic arthritis; severe chronic plaque psoriasis

Ustekinumab (45 mg/0.5 mL injection, 0.5 mL syringe; 45 mg/0.5 mL injection, 0.5 mL vial, 90 mg/mL injection, 1 mL syringe; 130 mg/26 mL injection, 26 mL vial) (Wezlana®) is a new biosimilar now listed on the PBS for the treatment of severe Crohn disease; moderate to severe ulcerative colitis; complex refractory Fistulising Crohn disease; severe psoriatic arthritis and severe chronic plaque psoriasis.

Pulmonary Arterial Hypertension (PAH)

Ambrisentan tablets, bosentan tablets, epoprostenol injection, iloprost inhalation solution, macitentan tablets, sildenafil tablets and tadalafil tablets for the treatment of PAH have had an update to their restrictions. Applications for initial monotherapy treatment, initial dual or triple therapy treatment (excluding selexipag) can be made using the Online PBS Authorities system or in writing. Applications to transition to dual or triple therapy, change or continue treatment (excluding selexipag) can be made using the Online PBS Authorities system or by telephone.

Applications for initial and continuing treatment of triple therapy (including selexipag) can be made using the Online PBS Authorities system or by telephone.

Acute allergic reaction with anaphylaxis

Adrenaline (epinephrine) (1 mg/actuation nasal spray, 2 x 1 actuation; 2 mg/actuation nasal spray, 2 x 1 actuation) (neffy®) is now listed on the PBS for the treatment of acute allergic reaction with anaphylaxis. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Resected non-small cell lung cancer (NSCLC); Stage IIIB (locally advanced) or Stage IV (metastatic) non-small cell lung cancer (NSCLC)

Alectinib (150 mg capsule, 4 x 56) (Alecensa®) is now listed on the PBS for the treatment of resected NSCLC and Stage IIIB (locally advanced) or Stage IV (metastatic) NSCLC. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Chronic severe disabling pain; severe disabling pain in palliative care

Methadone (methadone hydrochloride 5 mg tablet, 20) (METHADONE-AFT®) is now listed on the PBS for the treatment of chronic severe disabling pain and for severe disabling pain in palliative care. Authority applications for initial and continuing treatments of chronic severe disabling pain are Authority Required (STREAMLINED). Authority applications for patients with severe disabling pain undergoing palliative care can be made using the Online PBS Authorities system or by telephone.

Generalised convulsive status epilepticus

Midazolam (2.5 mg/0.25 mL oral liquid, 0.25 mL syringe) (Zyamis®) is now listed on the PBS for the treatment of generalised convulsive status epilepticus. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Non-small cell lung cancer (NSCLC)

Osimertinib (40 mg tablet, 30; 80 mg tablet, 30) (Tagrisso®) is now listed on the PBS for the treatment of NSCLC. Authority applications for treatment can be made using the Online PBS Authorities system or by telephone.

Early HER2 positive breast cancer

Pertuzumab (420 mg/14 mL injection, 14 mL vial) (Perjeta®) is now listed on the PBS for the treatment of early HER2 positive breast cancer. Authority applications for initial and continuing treatments can be made using the Online PBS Authorities system or by telephone.

Relapsed or chemotherapy refractory Peripheral T-cell lymphoma

Romidepsin (10 mg injection [1 vial] (& inert substance diluent [2 mL vial], 1 pack) (ROMIDEPSIN-REACH®) is now listed on the PBS for the treatment of relapsed or chemotherapy refractory Peripheral T-cell lymphoma. Authority applications for initial, continuing and grandfather treatments can be made using the Online PBS Authorities system or by telephone.

Locally advanced or metastatic cholangiocarcinoma

Futibatinib (4 mg tablet, 35) (Lytgobi®) is now listed on the PBS for the treatment of locally advanced or metastatic cholangiocarcinoma. Prescriptions for treatment are Authority Required (STREAMLINED).

Type 1 diabetes

Insulin degludec (100 units/mL injection, 5 x 3 mL cartridges) (Tresiba Penfill®) for the treatment of type 1 diabetes is now listed on the PBS as a Restricted benefit.

Malignancy

Cyclophosphamide (1 g injection, 1 vial; 2 g injection, 1 vial) (Cyclophosphamide (NorthStar, USA®)) is now listed on the PBS for the current supply shortage under Section 19A. It is listed as an unrestricted benefit.

Epilepsy

Phenobarbital (30 mg tablet, 100) (Phenobarbital Tablets, USP 30 mg (Rising Pharmaceuticals, USA®)) for the treatment of epilepsy is now listed on the PBS for the current supply shortage under Section 19A. It is listed as a Restricted benefit.

Infections

Benzathine benzylpenicillin (1.2 million units powder for injection, 1 vial) (Benzylpenicillin benzathine (Brancaster Pharma, UK®)) is now listed on the PBS for the current supply shortage under Section 19A. It is listed as an unrestricted benefit.

Additions to PBS listings for 60-day prescriptions

The following medicine is now available for 60-day prescriptions on the PBS:

Pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) infection

TENOFOVIR DISOPROXIL + EMTRICITABINE (tenofovir disoproxil fumarate 300 mg + emtricitabine 200 mg tablet) (CIPLA TENOFOVIR + EMTRICITABINE 300/200®; TENOFOVIR/EMTRICITABINE 300/200 APX®), TENOFOVIR/EMTRICITABINE 300/200 ARX®); (tenofovir disoproxil succinate 301 mg + emtricitabine 200 mg tablet) (Tenofovir/Emtricitabine Sandoz 301/200®); (tenofovir disoproxil maleate 300 mg + emtricitabine 200 mg tablet) (Tenofovir Disoproxil Emtricitabine Viartis 300/200®) is now available for 60-day prescriptions on the PBS for the treatment of PrEP against HIV. It is listed as a Restricted benefit.

1 July 2026 delisted PBS listings**Anaemia associated with intrinsic renal disease**

Epoetin beta (2000 units/0.3 mL injection, 6 x 0.3 mL syringes); 3000 units/0.3 mL injection, 6 x 0.3 mL syringes; 4000 units/0.3 mL injection, 6 x 0.3 mL syringes; 5000 units/0.3 mL injection, 6 x 0.3 mL syringes; 6000 units/0.3 mL injection, 6 x 0.3 mL syringes; 10 000 units/0.6 mL injection, 6 x 0.6 mL syringes) (NeoRecormon®) for the treatment of anaemia associated with intrinsic renal disease has been delisted with no supply only arrangements in place.

IMPORTANT INFORMATION



PBS Authorities – Changes from 1 July 2026

Treatment of severe Crohn's disease (for patients 18 years and older)

Authority applications for **initial, change/recommencement and continuing treatments** can now be made using the Online PBS Authorities system or by telephone. Authority applications for extended induction period (upadacitinib & vedolizumab IV only) can be made using the Online PBS Authorities system or by telephone. Prescriptions for continuing treatment (biosimilar brands of adalimumab, infliximab IV and ustekinumab only) and continuing treatment or switching treatment from IV to SC (infliximab SC only) are Authority required (STREAMLINED).

Note: These changes mean that the Adult Crohn Disease Activity Index (CDAI) sheet to calculate the severity of Crohn's disease is no longer required to be submitted. Prescribers will be required to provide CDAI score or evidence as per the restrictions.

PBS S100 Growth Hormone Program

From 1 July 2026, applications for authority to prescribe growth hormone can be made in real time using the Online PBS Authorities system or in writing. For online applications made through the Online PBS Authorities system, the assessment is made and returned in real time. Online authority applications can be submitted 24 hours a day, 7 days a week.

Prescribers may submit written applications in Health Professional Online Services (HPOS) using the form upload function or by post. Prescribers submitting authority applications by post will need to factor in the time required for the application to be received by Services Australia and the time it will take for the authority approval details to be communicated to the prescriber.



Integrated clinical and prescribing software

Several clinical and prescribing software developers now have products available for use to request PBS authority approval directly from your clinical and prescribing software. This means you can request PBS authority approval as part of generating the authority prescription rather than calling, applying in writing or self-serving through the PBS Authorities tile in HPOS. For more information, speak with your software provider.



Submitting Pharmaceutical Benefits Scheme (PBS) Written Applications through Health Professional Online Services (HPOS) form upload

When submitting PBS authority forms through HPOS form upload, it is important to select the correct Form Category. For PBS patients, select PBS Authorities. For DVA patients, select RPBS Authorities. Remember that only yourself or your delegate/s are authorised to upload PBS and RPBS Authority applications.

Make sure you've:

- linked your prescriber number to your Provider Digital Access (PRODA) account for HPOS; and
- Set up your delegations in HPOS.

Visit servicesaustralia.gov.au/HPOS for more information on how to Link your Health Identifiers to HPOS and Manage delegations.



PBS Authorities items criteria

Under the PBS, medicines are made available based on recommendations from the Pharmaceutical Benefits Advisory Committee (PBAC). Patients must meet the set criteria to be eligible for PBS subsidised medicines. Services Australia are unable to provide approval for an Authority Required medication where a patient does not meet the criteria established by PBAC.

If you have concerns or questions about the eligibility criteria set by the PBAC, you can contact the Department of Health, Disability and Ageing by email at pbs@health.gov.au.

REMINDERS



PBS Authorities – written authority application forms

To align with PBS listing changes, forms are updated on the first of the month. Using the most recent form will help avoid delays in obtaining authority approval. Search the Services Australia website to access the most recent forms.



Correct PBS item code

When requesting PBS authorities via the Online PBS Authorities system, ensure you have selected the correct medicine to match what is on the prescription. This will avoid delays with providing patients with the medication they require.



Ensuring you are providing accurate data

It's important to ensure you are providing accurate and up to date information when completing an authority application. Failure to do so may result in your authority request being rejected.



For more information about the Online PBS Authorities system visit www.servicesaustralia.gov.au/hppbsauthorities

Services Australia has a broad range of educational resources on the Health Professional Education Resources website. This includes simulations, podcast and an infographic on the Online PBS Authorities system. Visit <https://hpe.servicesaustralia.gov.au/pharmaceutical-benefits-scheme.html>

Visit servicesaustralia.gov.au/hpwrittenauthoritydrugs on the Services Australia website to find the most up to date authority application form for each drug, program or condition.